In This Store
Feihe Group is a privately held Chinese supplier specializing in the sourcing, R&D, manufacturing, sales and marketing of high quality pharmaceutical ingredients and fine chemicals. Founded in 1997 and with its constant and stable development, today Feihe comprises five branches.
Feihe Xiamen is the primary branch of Feihe, with nearly two decades experience of serving the pharmaceutical and fine chemical industry, Feihe Xiamen has laid solid foundation for Feihe Group and won good reputation among worldwide customers.
Feihe Group established its second branch in the metropolis of Shanghai in 2008, which is Feihe Shanghai. Feihe Shanghai is a professional team with extensive chemical knowledge and background.
Feihe Shanghai and Xiamen jointly play the role as the sales and marketing branches for Feihe Group.
Feihe Pharmatech has been in operation since 2010. Our skilled R&D and manufacturing team provide custom synthesis, process development and contract manufacturing for pharmaceutical ingredients, special chemicals and new compounds.
Feihe Group has two overseas branches, which are Feihe Hong Kong and Feihe United kingdom. Feihe United kingdom is in charge of the Reach pre-registration and registration. Feihe Hong Kong, due to its superior location, is another convenient channel connecting Feihe with overseas markets.
Today, with the joint effort of all branches, Feihe’s sales network are present throughout the world, including European Union, United States, Japan, India, Korea, Brazil etc.
Meanwhile, Feihe Xiamen and Shanghai started the function of importing API years ago. Thanks to our deep understanding of domestic market and broad network here , Feihe is able to pinpoint promising API and import it into Chinese huge market.
Year of Establishment: 1997
Total Assets(USD): choose not to disclose
Total Number of Staff: less than 10 person
Main Competitive Advantages:
Other Competitive Advantages:
Patents and Copyrights:
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: